Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical research on the combined use of SHR-1826 with other drugs for injection has been approved.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-1826, Adebril monoclonal antibody injection, and Bevacizumab monoclonal antibody injection. The companies will soon begin a multicenter, open-label phase Ib/II clinical study to evaluate the safety, tolerability, and effectiveness of injection SHR-1826 in combination with other anti-tumor treatments in patients with solid tumors.